Irla N, Schneiter T, Haneke E, Yawalkar N
Department of Dermatology, Bern University Hospital and University of Bern, Bern, Switzerland.
Case Rep Dermatol. 2010 Oct 21;2(3):173-176. doi: 10.1159/000321419.
Etanercept is a fully human tumor necrosis factor a receptor fusion protein that binds tumor necrosis factor a with greater affinity than natural receptors. Biologics are widely used in the treatment of psoriasis and psoriasis arthritis and may represent a new therapeutic option for some patients with psoriatic nail disease. CASE REPORT: We report a case of lichen planus limited to the toe nails successfully treated with etanercept monotherapy. CONCLUSION: The significant improvement of our case suggests that etanercept is an effective treatment modality for lichen planus limited particularly to the nails. Further controlled studies are needed to establish the effectiveness and therapeutic regimes.
依那西普是一种全人源肿瘤坏死因子α受体融合蛋白,其与肿瘤坏死因子α的结合亲和力高于天然受体。生物制剂广泛应用于银屑病和银屑病关节炎的治疗,对于一些银屑病甲病患者可能是一种新的治疗选择。病例报告:我们报告1例仅累及趾甲的扁平苔藓患者,采用依那西普单药治疗取得成功。结论:我们的病例显著改善表明,依那西普是治疗尤其局限于指甲的扁平苔藓的一种有效治疗方式。需要进一步的对照研究来确定其有效性和治疗方案。